Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Medical Crossfire®: Progressive Fibrosis-Interstitial Lung Disease (PF-ILD): Navigating the Complex Pathways to Diagnosis, Management, and Emerging Therapies

Release Date: June 30, 2019
Expiration Date: June 30, 2020
Media: Internet - based

Activity Overview

Interstitial lung diseases (ILDs) are a diffuse group of over 200 lung disorders which are associated with substantial morbidity and mortality. Most of them are rare but when pulmonary fibrosis predominates, they are particularly difficult to treat and manage and patients bear a severely diminished quality of life. Idiopathic pulmonary fibrosis is considered the classic presentation of the fibrotic interstitial lung diseases but other ILD etiologies exhibit similarities with the presence of worsening pulmonary fibrosis and respiratory symptoms, declining lung function, and resistance to immunomodulatory treatments related to other diseases such as rheumatoid arthritis and systemic sclerosis or to environmental exposures and unknown causes.

Early diagnosis and disease intervention are critical for these patients, but lengthy delays and misdiagnoses are common. Typical presenting symptoms are more likely to be an indication of a common respiratory or cardiovascular condition and clinicians will rule out those diagnoses by exposing patients to costly and invasive testing with limited consideration for the possibility of a rare interstitial lung disease. Diagnosis of ILDs is complex and involves careful exclusion of alternative etiologies by a multidisciplinary team integrating findings from clinical, radiologic, and pathologic exam. During this Medical Crossfire®, expert faculty specializing in pulmonology, rheumatology and diagnostic radiology will share their clinical practice insights for making an accurate diagnosis and considering treatment with antifibrotics that can delay disease progression. Faculty will then elaborate on strategies for clinician-patient collaboration to individualize a comprehensive treatment program that addresses comorbidities, patient expectations and best possible quality of life.

Benefits of Participating

  • Gain familiarity with etiologies and early recognizable signs and symptoms of interstitial lung diseases
  • Learn the role of antifibrotics in disease management and how to set patient treatment expectations
  • Understand the benefits of a multidisciplinary approach to diagnosis and ongoing disease management

CME Activity Table of Contents

  • Pre-activity test
  • Module 1: Overview and faculty introductions
  • Module 2: Pathogenetic mechanisms of progressive fibrosing ILDs
  • Module 3: Multidisciplinary diagnosis of fibrosing interstitial lung diseases
  • Module 4: Treatment of PF-ILDs: Considerations, clinical trials, goals and patient expectations
  • Module 5: Clinician-patient collaboration in disease management for an individualized approach
  • Post-activity test
  • Evaluation

Acknowledgement of Commercial Support

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This online educational activity is directed toward pulmonologists, rheumatologists, radiologists, clinical immunologists, allergists, specialty nurse practitioners, physician assistants, primary care clinicians and other healthcare professionals involved in the treatment of patients with PF-ILD.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Identify key mechanisms underlying the varied forms of PF-ILD, clinical presentation and management.
  • Assess the pathological patterns of fibrosis in PF-ILD and their role in defining disease etiology and subsequent management.
  • Examine the role of current and emerging agents in the treatment of patients with PF-ILDs.
  • Implement team-based strategies to improve individualization of treatment plans for patients with PF-ILD.

Faculty, Staff, and Planners’ Disclosures


Steven Nathan
Steven Nathan, MD
Medical Director, Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Professor of Medicine, Virginia Commonwealth University
Inova Fairfax Campus

Disclosures: Grant Research Support: Biogen; Consultant: Roche-Genentech, Boerhinger-Ingelheim, Galapagos, Promedior, Bellerophon, United Therapeutics; Speakers Bureau: Roche-Genentech, Boerhinger-Ingelheim.

Ami N. Rubinowitz
Ami N. Rubinowitz, MD
Associate Professor Thoracic Imaging Section
Department of Radiology and Biomedical Imaging
Yale University School of Medicine, Yale-New Haven Hospital
New Haven, CT

Disclosures: Ami Rubinowitz has no relevant financial relationships with commercial interests to disclose.

Joshua J. Solomon
Joshua J. Solomon, MD
Associate Chief, Section of Critical Care
Associate Professor
Department of Medicine
Division of Pulmonary, Critical Care & Sleep Medicine
National Jewish Health
Denver, CO

Disclosures: Grant Research Support: Pfizer, Boehringer Ingelheim; Speakers Bureau: Genentech.

Monique Hinchcliff
Monique Hinchcliff, MD, MS
Associate Professor of Medicine
Director of Clinical Research
Director of Yale Scleroderma Program
New Haven, Connecticut

Disclosures: Monique Hinchcliff has no relevant financial relationships with commercial interests to disclose.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By